Skip to content

Valneva

  • About Us
    About Us Advancing vaccines for better lives Learn More
    • Our Strategy
    • Our Responsibility
    • Our Team
  • Products
    Products Focusing on vaccines for infectious diseases with major unmet needs Learn More
    • Japanese Encephalitis Vaccine
    • Cholera Vaccine
    • COVID-19 Vaccine
    • Marketing and Distribution
    • Manufacturing and Services
  • R&D
    R&D Dedicated to innovation in vaccine research and development Learn More
    • Pipeline
    • Lyme Disease – VLA15
    • Chikungunya – VLA1553
    • Zika – VLA1601
    • Clostridium Difficile – VLA84
    • Expanded Access Policy
    • Scientific Publications
  • Investors
    Investors Learn More
    • Events and Presentations
      • Calendar
      • Corporate Presentations
    • Financial & Filings
      • Financial Reports
      • SEC Filings
    • Press Releases
    • Corporate Governance
      • Corporate Governance
      • Corporate Compliance & Ethics
    • Regulated Information
    • Stock Information
      • Stock Price
      • Analysts
      • Shareholder Structure
      • Vienna Stock Exchange Delisting
    • General Meetings
      • 2022 Combined General Meeting
      • June 23, 2022 Special Meeting
      • General Meeting Archive
    • Videos and Webcasts
    • FAQ
    • Contact
  • Media
    Media Press releases, latest news and media resources Learn More
    • Press Releases
    • In The News
    • Media Kit
    • Media Contacts
  • Careers
Contact
  • EN
  • FR
  • | DE
Search

Videos and Webcasts

Webcast of Valneva's Investor Day (December 6, 2022)
Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates (Webcast, November 10, 2022)
CEO Thomas Lingelbach Comments on Valneva's 2022 Half-Year Results
Valneva-CEO im Interview: Ganzvirusimpfstoff könnte noch entscheidend sein (in German)
EC APA Update (Webcast, May 16, 2022 - 3pm CEST)
Q1 2022 Financial Results and Corporate Updates (Webcast, May 5, 2022)
First look at Valneva's new Hans Wigzell Vaccine Facility in Sweden
2021 Financial Results and Corporate Updates (Webcast, March 24, 2022)
Valneva's CEO Thomas Lingelbach comments on Valneva's 2021 achievements and its focus for 2021
Valneva's Chief Medical Officer Juan Carlos Jaramillo, MD, comments on vaccine development at Valneva
Valneva Presentation at the H.C. Wainwright BIOCONNECT 2022 Conference (January 10, 2022)
2021 Combined General Meeting (Webcast - Audio in French) - June 23, 2021
Valneva - Now on Nasdaq
Extraordinary General Meeting 2020, December 22, 2020 at 2:00 p.m. CET
Valneva Stands with Science
Nantes : un laboratoire progresse dans la recherche d'un vaccin contre la maladie de Lyme (in French)
Annual General Meeting, June 17, 2020 (Webcast - Audio in French)
Company Video

Valneva

  • About Us
  • Products
  • R&D
  • Investors
  • Media
  • Careers
Related Websites
  • Valneva Canada
  • Valneva UK
  • Valneva Austria
  • Valneva USA
  • Valneva Nordic
  • Valneva France
Contact
© 2023 Valneva SE. All rights reserved.
  • Legal Notice
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • 1907-00-VLA-002 | 11-JUL-2019
We use cookies to improve the functionality and user experience of the website and to analyse the traffic. You can find detailed information in our Privacy Policy.
ACCEPT CHANGE MY PREFERENCES
Privacy & Cookies Policy

Your privacy is important to us

Cookies are very small text files that are stored on your computer when you visit a website. We use cookies for a variety of purposes and to enhance your online experience on our website (for example, to remember your account login details).

You can change your preferences and decline certain types of cookies to be stored on your computer while browsing our website. You can also remove any cookies already stored on your computer, but keep in mind that deleting cookies may prevent you from using parts of our website.

More information

For any queries in relation to our policy on cookies and your choices, please contact us.

To find out more, please visit our Cookies Policy.
Strictly necessary cookies
Always Enabled
These cookies are essential to provide you with services available through our website and to enable you to use certain features of our website.

Without these cookies, we cannot provide you certain services on our website.
Tracking and performance cookies
These cookies are used to collect information to analyze the traffic to our website and how visitors are using our website.

For example, these cookies may track things such as how long you spend on the website or the pages you visit which helps us to understand how we can improve our website site for you.

The information collected through these tracking and performance cookies do not identify any individual visitor.
SAVE & ACCEPT